Skip to main content

Nuvation Bio Inc.

NUVB
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001811063

No open-market purchases or sales by Nuvation Bio Inc. insiders were filed in the last 90 days; 259 institutions reported holding it in 13F filings for Q3 2026, worth $1.40B in total; 3 superinvestors hold it, including Duquesne Family Office and Abrams Capital.

Key figures

Market capClose on Nov 20, 2026
$1.34B
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +19 vs. previous quarter
259
13F valueReported value at the end of Q3 2026
$1.40B
Superinvestors holdingAt the end of Q3 2026
3

Price chart

From SEC filings, in USD.

Revenue, FY2025
$62.9M
+699.0% year over year
Net income, FY2025
-$204.6M
No comparable prior period
Free cash flow, FY2025
-$181.4M
No comparable prior period
Revenue, Q3 FY2026
$45.0M
+242.6% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $204.6M (325.3% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
62.0M
Shares sold short
Change
−1.22M
−1.9% vs. previous
Days to cover
12.50
At average daily volume

Superinvestors holding NUVB, Q3 2026

Go to the superinvestors tab

3 superinvestors report holding Nuvation Bio Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Duquesne Family Office

Stanley Druckenmiller

0.3%

Nuvation Bio Inc.'s share of the portfolio

Shares
2,269,900
Value
$12.7M

Abrams Capital

David Abrams

0.1%

Nuvation Bio Inc.'s share of the portfolio

Shares
1,270,504
Value
$7.11M
Other superinvestors holding NUVB (part 1)
SuperinvestorWeightValue
Greenlight Capital<0.1%$196.0K

Latest insider trades

See all insider trades

Open-market purchases and sales by Nuvation Bio Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 21, 2026 (view filing)4:49 PM ETAug 192 daysHattersley GaryCHIEF SCIENTIFIC OFFICERSSaleClass A Common Stock−100.0K$7.09−$709.2K−100.0%0 after10b5-1
Jun 24, 2026 (view filing)Jun 231 daySauvage PhilippeChief Financial OfficerSSaleClass A Common Stock−47.7K$6.01−$286.5K−79.0%12.7K after10b5-1
Jun 24, 2026 (view filing)Jun 231 dayMarkel StacyCHIEF PEOPLE OFFICERSSaleClass A Common Stock−125.0K$6.03−$753.8K−79.3%32.6K after10b5-1
Jun 24, 2026 (view filing)Jun 231 dayWentworth KerryCHIEF REGULATORY OFFICERSSaleClass A Common Stock−63.0K$6.02−$379.3K−54.3%53.0K after10b5-1
Jun 11, 2026 (view filing)Jun 92 daysMashal RobertDirectorPPurchaseClass A Common Stock+25.0K$4.73+$118.3K+12.5%225.0K after
Apr 21, 2026 (view filing)Apr 174 daysLiu DongfangCHIEF MEDICAL OFFICERSSaleClass A Common Stock−50.0K$5.02−$251.0K−73.5%18.0K after10b5-1
Apr 21, 2026 (view filing)Apr 174 daysWentworth KerryCHIEF REGULATORY OFFICERSSaleClass A Common Stock−36.8K$5.01−$184.1K−40.9%53.0K after10b5-1
Apr 8, 2026 (view filing)Apr 62 daysWentworth KerryCHIEF REGULATORY OFFICERSSaleClass A Common Stock−200.0K$4.52−$904.0K−79.1%53.0K after10b5-1
Dec 3, 2025 (view filing)Dec 12 daysLiu DongfangCHIEF MEDICAL OFFICERSSaleClass A Common Stock−150.0K$7.82−$1.17M−89.3%18.0K after
Nov 26, 2025 (view filing)Nov 25-261 dayLiu DongfangCHIEF MEDICAL OFFICERSSaleClass A Common Stock−20.0K$7.75−$155.0K−52.6%18.0K after2 lots

Top 10 13F holders, Q3 2026

See all 259 holders

The largest institutional positions in Nuvation Bio Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding NUVB in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC52,668,484$294.9M0.01%+438,189+0.8%Added
BlackRock, Inc.28,924,444$162.0M0.00%+1,293,607+4.7%Added
Decheng Capital LLC25,954,439$145.3M21.22%00.0%Unchanged
Vanguard Capital Management LLC12,152,903$68.1M0.00%+233,389+2.0%Added
Laurion Capital Management LP7,697,272$43.1M3.26%−122,741−1.6%Reduced
State Street Corp7,596,209$42.5M0.00%+225,415+3.1%Added
Omega Fund Management, LLC7,151,031$40.0M31.99%−930,058−11.5%Reduced
Geode Capital Management, LLC6,446,677$36.1M0.00%+201,872+3.2%Added
American Century Companies Inc4,519,041$25.3M0.01%+19,398+0.4%Added
Goldman Sachs Group Inc4,511,958$25.3M0.00%+2,607,272+136.9%Added

Holders of 5% or more of NUVB

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Nuvation Bio Inc..

Largest holders of NUVB from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G/A15.00%50.6M shares+1.50 ppfrom 13.50%May 10, 20218 filingsMay 12, 2025SEC
BlackRock, Inc.13G6.40%21.7M shares+1.50 ppfrom 4.90%Apr 28, 20252 filingsJul 17, 2025SEC